Acura Pharmaceuticals awarded $300,000 grant to develop Rx abuse deterrent technology

PALATINE, Ill. — Acura Pharmaceuticals last week announced that it has been awarded a $300,000 grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology. The Grant is based on a proposal submitted by the company to advance the development of a self-regulating hydromorphone tablet intended to deter abuse by excess oral consumption of the tablets.

 

Under the terms of the grant, the company must complete Phase I development by Feb. 28, 2015. Phase I of the project is intended to optimize the formulation in preparation for clinical testing in Phase II. 

 

NIDA funding of Phase II development, for which an application has already been submitted, will be contingent upon assessment by NIDA of the Phase I progress report and determination that the Phase I milestones were achieved, review and approval of other documents necessary for continuation and availability of funds.